The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045
Our study highlights the substantial burden and variations in MM incidence and mortality reflecting global disparities in diagnosis and treatment. Improved surveillance and better disease control is needed to mitigate the global impact of MM in the presence of population aging and growth.
Authors
- Charlene M. McShane (ORCID: https://orcid.org/0000-0001-8609-0788)
- Humberto V.S. Chaves
- Mathieu Laversanne (ORCID: https://orcid.org/0000-0002-1568-7218)
- Allini Mafra da Costa (ORCID: https://orcid.org/0000-0002-2993-7919)
- Freddie Bray (ORCID: https://orcid.org/0000-0002-3248-7787)
- Ariana Znaor (ORCID: https://orcid.org/0000-0002-5849-4782)
- Rafael Marcos‐Gragera (ORCID: https://orcid.org/0000-0001-9824-3657)
Institutions
- University of Ulster (GB)
- AC Camargo Hospital (BR)
- Josep Carreras Leukaemia Research Institute (ES)
- Luxembourg Institute of Health (LU)
- Institut Català d'Oncologia (ES)
- Institut d'Investigació Biomèdica de Girona (ES)
- Royal Victoria Hospital (GB)
- Victoria Hospital (GB)
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES)
- Royal Victoria Hospital (GB)
- Centre international de recherche sur le cancer (FR)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1093/jnci/djae321
- Citations
- 44
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 19.99